Cargando…
Beyond PD-1 Immunotherapy in Malignant Melanoma
For many years, the standard therapy for malignant melanoma was based mainly on surgical resection. Unfortunately, this treatment is curative only in the early localized stage of this malignancy. The metastatic stage of malignant melanoma still remains a huge therapeutic challenge. Despite the many...
Autores principales: | Kwiatkowska, Dominika, Kluska, Piotr, Reich, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522569/ https://www.ncbi.nlm.nih.gov/pubmed/30927248 http://dx.doi.org/10.1007/s13555-019-0292-3 |
Ejemplares similares
-
Convolutional neural networks for the detection of malignant melanoma in dermoscopy images
por: Kwiatkowska, Dominika, et al.
Publicado: (2021) -
YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
por: Kwiatkowska, Dominika, et al.
Publicado: (2022) -
Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021) -
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023) -
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)